Why is the Paradigm (ASX:PAR) share price climbing today?

The Paradigm (ASX: PAR) share price is up 2.8% after the company reported a loss in its first-half FY21 earnings. Here's a closer look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price gained ground today and is presently trading at $2.55 a share, a 2.82% bounce.

The share price increase comes after Paradigm released its 1HY21 financial results.

Here's the rundown of what we found out. 

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

Paradigm share price rises after company reports loss

Paradigm reported a net profit after taxes (NPAT) loss of $20.7 million for 1HY21. This compares to the $5.1 million loss reported for 1HY20.

The company advised that the increased NPAT loss was a product of the significant progress made with its osteoarthrosis (OA) and mucopolysaccharidosis (MPS) clinical programs.

Specifically, the company incurred the costs and expenses reflected in the NPAT loss in order to launch phase II and phase III trials for the treatment of MPS. Paradigm also allocated additional expenses to convene meetings pertaining to OA with the United States Food and Drug Administration and European Medicines Agency.

As of 31 December 2020, Paradigm posted $95.3 million worth of assets. $112.4 million in total assets was reported for the 1HY20 period.

Cash and cash equivalents totalled $85.2 million for 1HY21 compared to $80 million for 1HY20.

The company received a $3.4 million R&D tax incentive during 1Hy21.

Chief medical officer shares insight

Paradigm chief medical officer Dr Donna Skerrett commented on Paradigm's progress during the period, saying: 

During CY 2020, Paradigm conducted a number of non-clinical and clinical studies to provide updated information regarding drug characteristics, pharmacokinetics, and non-clinical toxicity as requested by the FDA in the company's first meeting with the agency in February 2020.

Paradigm has worked diligently to ensure it has all the necessary supporting non-clinical and clinical data and clinical development plan to support its IND submission in Q1 CY 2021.

Paradigm share price snapshot

Over the past year, the Paradigm share price has dropped about 26%.

The company's market capitalisation is $578.2 million. Paradigm currently has 225.9 million shares outstanding.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a sour end to the trading week this Friday.

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Broker Notes

Guess which ASX stock could more than triple in value according to Morgans!

A 285% return could be on the cards here according to the broker.

Read more »

A happy youngster holds a giant bag of carrots at a supermarket fruit and vegie section, indicating savings made by buying in bulk.
Opinions

2 ASX shares I'd buy if the market fell another 10%

Pullbacks are great times to buy...

Read more »

A group of friends push their van up the road on an Australian road.
52-Week Lows

This ASX 200 stock just hit a multi-year low. Here's what's behind the slide

CAR Group shares hit a multi-year low as selling continues.

Read more »

A man sitting at his dining table looks at his laptop and ponders the share price.
Materials Shares

ASX lithium shares 'compelling' as top broker adjusts ratings

UBS predicts the global oil shock caused by the war in Iran will drive higher demand for electric vehicles.

Read more »

a woman wearing a sparkly strapless dress leans on a neat stack of six gold bars as she smiles and looks to the side as though she is very happy and protective of her stash. She also has gold fingernails and gold glitter pieces affixed to her cheeks.
IPOs

The newest ASX gold company makes a strong debut on the bourse, up more than 20%

Shareholders would have to be happy with this first day.

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Dividend Investing

8% yield: The ASX is getting a new dividend stock that pays out monthly

This soon-to-be stock has averaged an 8% yield since 2016...

Read more »

Red buy button on an Apple keyboard with a finger on it.
Broker Notes

Brokers name 3 ASX shares to buy right now

Here's why brokers are feeling bullish about these three shares this week.

Read more »